MOTRIMAX 12 HOUR TABLETS

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

NAPROXEN SODIUM

Disponibbli minn:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

Kodiċi ATC:

M01AE02

INN (Isem Internazzjonali):

NAPROXEN

Dożaġġ:

220MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

NAPROXEN SODIUM 220MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

24/50/100/120/200/300/400

Tip ta 'preskrizzjoni:

OTC

Żona terapewtika:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0113934003; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2016-01-29

Karatteristiċi tal-prodott

_ _
_MotriMAX 12 HOUR™ Tablets Product Monograph _
_Page 1 of 32_
PRODUCT MONOGRAPH
MOTRIMAX 12 HOUR™ TABLETS
Naproxen Sodium Tablets USP
220 mg Tablets and Caplets
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
McNeil Consumer Healthcare
Division of Johnson & Johnson Inc.
88 McNabb St.
Markham, Ontario
L3R 5L2
Date of Preparation:
January 28, 2016
Control No: 191125
_ _
_MotriMAX 12 HOUR™ Tablets Product Monograph _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
11
OVERDOSAGE
...............................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 12
STORAGE AND STABILITY
.........................................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 14
PART II: SCIENTIFIC INFORMATION
..............................................................................
15
PHARMACEUTICAL INFORMATION
.........................................................................
15
CLINICAL TRIALS
...............................